No toxicology studies; xenogeneic GVHD POC study OBS-24-001 (18 studies, sublethally irradiated immunodeficient mice, human Tcons +/- Tregs)
“No toxicology studies were conducted for TREGZI.”
✓ VerifiedFDA pharmacology/toxicology review, p. 36Source ↗
Route in tox
Intravenous (clinical; mouse POC IV)
“HSPC DP (dose level: ≥1.0 x106 viable HSPCs/kg per patient) followed by Treg DP (dose level range: x 106 to 3.5 x 106 viable Tregs/kg per patient) are intravenously (IV) administered on day 0”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗